Haley Manley1, Simukayi Mutasa2, Peter Chang3, Elise Desperito2, Katherine Crew4, Richard Ha5. 1. Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX. 2. Department of Radiology, New York-Presbyterian/Columbia University Medical Center, New York, NY. 3. Department of Radiological Sciences and Center for Artificial Intelligence in Diagnostic Medicine, University of California, Irvine, Irvine, CA. 4. Departments of Medicine and Epidemiology, New York-Presbyterian/Columbia University Medical Center, New York, NY. 5. Department of Radiology and Breast Imaging Section, New York-Presbyterian/Columbia University Medical Center, New York, NY. Electronic address: rh2616@columbia.edu.
Abstract
INTRODUCTION: We investigated whether our convolutional neural network (CNN)-based breast cancer risk model is modifiable by testing it on women who had undergone risk-reducing chemoprevention treatment. MATERIALS AND METHODS: We conducted a retrospective cohort study of patients diagnosed with atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ at our institution from 2007 to 2015. The clinical characteristics, chemoprevention use, and mammography images were extracted from the electronic health records. We classified two groups according to chemoprevention use. Mammograms were performed at baseline and subsequent follow-up evaluations for input to our CNN risk model. The 2 chemoprevention groups were compared for the risk score change from baseline to follow-up. The change categories included stayed high risk, stayed low risk, increased from low to high risk, and decreased from high to low risk. Unordered polytomous regression models were used for statistical analysis, with P < .05 considered statistically significant. RESULTS: Of 541 patients, 184 (34%) had undergone chemoprevention treatment (group 1) and 357 (66%) had not (group 2). Using our CNN breast cancer risk score, significantly more women in group 1 had shown a decrease in breast cancer risk compared with group 2 (33.7% vs. 22.9%; P < .01). Significantly fewer women in group 1 had an increase in breast cancer risk compared with group 2 (11.4% vs. 20.2%; P < .01). On multivariate analysis, an increase in breast cancer risk predicted by our model correlated negatively with the use of chemoprevention treatment (P = .02). CONCLUSIONS: Our CNN-based breast cancer risk score is modifiable with potential utility in assessing the efficacy of known chemoprevention agents and testing new chemoprevention strategies.
INTRODUCTION: We investigated whether our convolutional neural network (CNN)-based breast cancer risk model is modifiable by testing it on women who had undergone risk-reducing chemoprevention treatment. MATERIALS AND METHODS: We conducted a retrospective cohort study of patients diagnosed with atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ at our institution from 2007 to 2015. The clinical characteristics, chemoprevention use, and mammography images were extracted from the electronic health records. We classified two groups according to chemoprevention use. Mammograms were performed at baseline and subsequent follow-up evaluations for input to our CNN risk model. The 2 chemoprevention groups were compared for the risk score change from baseline to follow-up. The change categories included stayed high risk, stayed low risk, increased from low to high risk, and decreased from high to low risk. Unordered polytomous regression models were used for statistical analysis, with P < .05 considered statistically significant. RESULTS: Of 541 patients, 184 (34%) had undergone chemoprevention treatment (group 1) and 357 (66%) had not (group 2). Using our CNN breast cancer risk score, significantly more women in group 1 had shown a decrease in breast cancer risk compared with group 2 (33.7% vs. 22.9%; P < .01). Significantly fewer women in group 1 had an increase in breast cancer risk compared with group 2 (11.4% vs. 20.2%; P < .01). On multivariate analysis, an increase in breast cancer risk predicted by our model correlated negatively with the use of chemoprevention treatment (P = .02). CONCLUSIONS: Our CNN-based breast cancer risk score is modifiable with potential utility in assessing the efficacy of known chemoprevention agents and testing new chemoprevention strategies.
Authors: Richard G Roetzheim; Ji-Hyun Lee; William Fulp; Elizabeth Matos Gomez; Elissa Clayton; Sharon Tollin; Nazanin Khakpour; Christine Laronga; Marie Catherine Lee; John V Kiluk Journal: Breast Date: 2014-12-06 Impact factor: 4.380
Authors: Jack Cuzick; Jane Warwick; Elizabeth Pinney; Ruth M L Warren; Stephen W Duffy Journal: J Natl Cancer Inst Date: 2004-04-21 Impact factor: 13.506
Authors: Maeve Mullooly; Babak Ehteshami Bejnordi; Andrew Beck; Mark E Sherman; Gretchen L Gierach; Ruth M Pfeiffer; Shaoqi Fan; Maya Palakal; Manila Hada; Pamela M Vacek; Donald L Weaver; John A Shepherd; Bo Fan; Amir Pasha Mahmoudzadeh; Jeff Wang; Serghei Malkov; Jason M Johnson; Sally D Herschorn; Brian L Sprague; Stephen Hewitt; Louise A Brinton; Nico Karssemeijer; Jeroen van der Laak Journal: NPJ Breast Cancer Date: 2019-11-19
Authors: Julia E McGuinness; Vicky Ro; Simukayi Mutasa; Samuel Pan; Jianhua Hu; Meghna S Trivedi; Melissa K Accordino; Kevin Kalinsky; Dawn L Hershman; Richard S Ha; Katherine D Crew Journal: Breast Cancer Res Treat Date: 2022-05-16 Impact factor: 4.872